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Abstract
Background: Selected and multiple reaction monitoring involves monitoring a multiplexed assay of proteotypic
peptides and associated transitions in mass spectrometry runs. To describe peptide and associated transitions as
stable, quantifiable, and reproducible representatives of proteins of interest, experimental and analytical validation is
required. However, inadequate and disparate analytical tools and validation methods predispose assay performance
measures to errors and inconsistencies.
Results: Implemented as a freely available, open-source tool in the platform independent Java programing language,
MRMPlus computes analytical measures as recommended recently by the Clinical Proteomics Tumor Analysis
Consortium Assay Development Working Group for “Tier 2” assays – that is, non-clinical assays sufficient enough
to measure changes due to both biological and experimental perturbations. Computed measures include; limit of
detection, lower limit of quantification, linearity, carry-over, partial validation of specificity, and upper limit of
quantification.
Conclusions: MRMPlus streamlines assay development analytical workflow and therefore minimizes error predisposition.
MRMPlus may also be used for performance estimation for targeted assays not described by the Assay Development
Working Group. MRMPlus’ source codes and compiled binaries can be freely downloaded from https://bitbucket.org/
paiyetan/mrmplusgui and https://bitbucket.org/paiyetan/mrmplusgui/downloads respectively.
Background
Selected or Multiple reaction monitoring (SRM and MRM)
mass spectrometry is the most widely used MS-based tar-
geted proteomic approach. In contrast to discovery proteo-
mics [1–6], targeted proteomics strategies entail limiting
the number of features monitored and optimizes chroma-
tography, instrument tuning, and acquisition methods to
achieve high sensitivity [7]. Its advantages over traditional
low-throughput quantitative approaches such as ELISA,
Western blotting, and immunohistochemistry include
multiplexing, a precise relative and absolute quantifica-
tion of endogenous analytes, no antibody requirement,
and an ability to detect unmodified and posttranslation-
ally modified forms of proteins [8–13]. These limita-
tions and opportunities presented by SRM/MRM are
well articulated by Shi et al. [14]. As surrogates to protein
expression level quantification methods such as mRNA
microarray and RNASeq methods fall short of an ability to
detect posttranslationally modified proteins, the demand
for SRM or MRM-based analytical approaches is antici-
pated to increase [7].
Similar to parallel reaction monitoring (PRM), MRM
typically involves monitoring a multiplexed assay of pro-
teotypic peptides. However under conditions that permit
high resolution and high mass accuracy, only a set of
preselected transitions are monitored in MRM as opposed
to all transitions in PRM [15, 16]. An MRM assay develop-
ment workflow may be broadly sub-divided into a pre-mass
spectrometry acquisition phase and a post-acquisition
phase. The pre-acquisition phase includes, 1) generation
of target protein list, 2) selection of proteotypic peptides
and 3) an experimental design step [17]. The post-
acquisition phase recently described by Colangelo et al
[7] entails four major steps; 1) peak detection, integration
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and quantification, 2) data quality assessment, 3) data
visualization and exploratory analysis, and 4) fold change/
statistical significance analysis.
Irrespective of the targeted proteomics approach
employed, the complexities of media within which moni-
tored proteotypic peptides that represent proteins of inter-
est reside result in the somewhat unpredictable analytical
behavior of peptides and transitions. Thus, it is important
that experimental and analytical validation is performed to
describe peptides and associated transitions as stable,
quantifiable, and reproducible representatives of proteins
of interest.
To standardize and validate quantifiable targeted mass
spectrometry-based peptide and protein quantifications,
the National Cancer Institute (NCI) National Institutes of
Health through the Clinical Proteomic Tumor Analysis
Consortium (CPTAC) Assay Development Working
Group (ADWG) recently described guidelines, experiments
and analytical measures for MRM assay characterization
[18]. Extending previously published guidelines and studies
[19, 20], the described guidelines ensure some levels of con-
fidence for assayed peptides and proteins in quantitative
targeted proteomics studies.
Currently available commercial, proprietary tools and
open source, vendor-neutral analytical tools for post-
data acquisition processing are extensively described in
Cham et al [21], Brusniak et al [17], Colangelo et al [7]
and Mani et al [19]. Though these tools are highly cred-
ible in addressing individual analytical challenges, we
found no suitable standalone, platform-independent tool
that readily implements the CPTAC ADWG’s recommen-
dation for the evaluation of assay performance. However,
Skyline [22], described as the most complete open source
platform addressing a great deal of the analytical require-
ments of an MRM assay development protocol, provided
a sufficient basis for the development of MRMPlus.
Streamlining workflow (Fig. 1) and minimizing error
predisposition, MRMPlus takes as input, Skyline derived
preprocessed files (Additional file 1: Table S1), in addition
to user defined metadata files (Additional files 2 and 3:
Tables S2 and S3) to compute analytical and validation
measures as recommended and described in the CPTAC
ADWG published guidelines (https://assays.cancer.gov/
guidance-document/).
Although MRMPlus was conceptualized and imple-
mented to compute the performance of assays developed
according to guidelines established by the CPTAC Assay
Development Working Group, it may also be used for per-
formance calculations for targeted assays not described by
the Working Group.
Implementation
We implemented MRMPlus in the platform-independent
Java programing language (Fig. 2). For statistical evaluations,
we utilized classes defined in the Apache Commons
Mathematics library [23]. For visualizations, we utilized
Java classes defined in the JFreeChart library [http://
www.jfree.org/jfreechart/].
Inputs to the program include Skyline-derived output
files in tab-delimited format (Additional files 1 and 4:
Tables S1 and S4), a user defined experiment metadata
(Additional file 2: Table S2), and a dilution information
data file (Additional file 3: Table S3). Current implemen-
tation of MRMPlus computes analytical measures for
“Response Curve” and “Mini-Validation of Repeatability”
experiments according to the ADWG’s current specifica-
tions (Additional files 5 and 6: Tables S5 and S6). The
response curve serves to identify the lower limit of
quantification (LLOQ), the limit of detection (LOD), and
the linear range of a peptide of interest in a multipoint
serial dilution of a biological replicate or matrix. The
mini-validation of repeatability experiments attempt to
replicate peptide measurements within a complex mix-
ture over multiple days. Its derived metrics approximate
the variability of the assay in real-life practice.
Default runtime initiated interface to MRMPlus accepts
inputs to compute “Response Curve” analytical measures
and the ‘More Options’ button instantiates the “Mini-
Validation of Repeatability” module (Fig. 2). Users may
modify the configuration file (MRMPlus.config) in the
application package to set runtime default options.
Setting the ‘Visualize Results’ option on the ‘More
Options’ panel to ‘TRUE’ instructs MRMPlus to gener-
ate performance associated visualizations (Fig. 2). MRMPlus
generates 8 visualization panels to provide a global per-
spective of assay performance across all assayed peptide
transitions. In addition, MRMPlus provides peptide-specific
(‘Response Curve’ and ‘Repeatability’) performance visuali-
zations. (Additional files 7: Figure S1 and Additional file 8:
Figure S2).
Ethics approval
The experimental work that was conducted in this study
did not require ethics approval. No patient-derived speci-
mens were used to generate the data for the development
of MRMPlus. All of the data were derived from formerly
N-linked glycopeptides enriched from commercially-
available serum and spiked with crude peptides.
Results and discussions
To demonstrate MRMPlus’ capabilities, we employed it
to compute the assay performance metrics on our panel
of formerly N-linked glycopeptides. Peptides were selected
from in-house discovery phase proteomic experiment ana-
lyses of prostate cancer tissues and serum studies. MRM
assays to these were developed using commercially available
serum and heavy labeled synthetic peptides as spiked-ins.
(Please see https://assays.cancer.gov/guidance-document/
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for detailed description of experiments). Here in this case
study, we subset fifteen of the profiled peptides and their
respectively associated transitions for MRMPlus’ demon-
stration purpose.
The current implementation of MRMPlus outputs re-
sults for ADWG-defined experiments’ ‘Response Curve’
and ‘Mini-Validation of Repeatability’. For ‘Response
Curve’ estimations, our assay experiments were performed
in triplicates over seven dilution ranges (Fig. 3). For
‘Mini-validation of Repeatability’ assay experiments were
similarly performed in triplicates, at three dilution
(concentration) levels – “High”, “Medium”, and “Low”.
These were repeated on five different days (Fig. 4). In
both ‘Response Curve’ and ‘Mini-validation of Repeat-
ability’, we assessed three transitions for each peptide.
MRMPlus computes performance estimates on two levels
for each targeted peptide: 1) each associated transition
level and 2) the summation observed transition values.
Computed results are presented in tables in which the
rows are performance measures for the respectively assayed
peptide transition, and the columns are the computed mea-
sures of analytical performance. (Additional file 5: Table S5,
and Additional file 6: Table S6). It should be noted that no
absolute values are reported when the peptide transition
values are summed with respect to ‘PVSpec.maxDeviation’,
‘PVSpec.meanAtMaxDev’, ‘PVSpec.dayAtMaxDev’, and
‘PVSpec.concLevelAtMaxDev’ performance measures,
because these are specific to transitions.
For ‘Response Curve’ performances, limit of detection
across peptide transitions span several magnitudes with
minimum LOD reported as 0.000524, and maximum
reported as 2293.62 (Additional file 5: Table S5, ‘LOD.-
value’ column). In all cases, LOD was assessed using
spiked-in concentrations (Additional file 5: Table S5,
‘LOD.usedSpiked’ column) as pre-curve blank mass
spectrometry runs reported no detectable levels. This is
Fig. 1 MRMPlus Concept/Flow Diagram. Mass spectrometry data are first preprocessed in Skyline™ and subsequently fed as input to MRMPlus. In
addition, MRMPlus takes as inputs, user-defined experiment metadata and a serial dilution information file
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possibly due to the mass spectrometer's sensitivity or
resolving power. A lower of limit of quantification
(Additional file 5: Table S5, ‘LLOQ.CaliPoint’ column)
could not be estimated for peptide transitions YLGN
ATAIFFLPDEGK (2.b9.1), AGPNGTLFVADAYK (2.y10.1),
and INNTHALVSLLQNLNK (3.b6.1). We observed an
almost absolutely linear response across all transitions
(Additional file 5: Table S5, ‘Curve.Rsquared’ and
‘Curve.SlopeStdErr(%)’ columns) with minimum stand-
ard error percent of the slope of the response curve re-
ported as 0.0030 % and maximum as 4.3979 %.
For ‘Mini-Validation of Repeatability’, MRMPlus re-
ports the intra-assay coefficient of variation, inter-assay
coefficient of variation, and the total coefficient of vari-
ation for each peptide transition at respectively specified
low, medium, and high concentration levels. The lowest
total CV at the validated lower limit of quantification
3.3918 was found associated with peptide transition
YLGNATAIFFLPDEGK (2.y8.1) (Additional file 6:
Table S6, ‘ValidatedLLOQ.concLevel’ and ‘totalCV.Me’
columns).
The CPTAC ADWG recommends that for a transition
to be deemed specific to a peptide, in all samples above
the lower limit of quantification, no transition ratio
(ratios of peak areas of different transitions of same
peptide) in each sample at all concentrations should de-
viate >30 % from the mean. MRMPlus reports the max-
imum deviation percentage observed for each transition;
such that a deviation above the specified 30 % indi-
cates non-specificity of such transition to the associ-
ated peptide.
Thomas et al. [24] – recently published, provides a
complete description of a study of ours demonstrating
the utility of MRMPlus.
Comparing MRMPlus to PanoramaWeb
We compared MRMPlus’ results with comparable outputs
derived from PanoramaWeb [25] on our data (Additional
file 9: Table S7 and Additional file 10: Table S8). MRMPlus
and PanoramaWeb derived exactly the same results for es-
timation of ‘Repeatability’ performance. With respect to
‘Response Curve’ performance estimation MRMPlus’ and
PanoramaWeb results varied. These may particularly be
due to their differing methods of estimating linearity.
However, Both MRMPlus’ and PanoramaWeb report
excellent statistical measure of how close their data are
fitted to the regression line – indicated by similar R-
squared estimation.
Fig. 2 MRMPlus’ Graphics User Interface. In addition to user-defined and Skyline input files, MRMPlus’ interface requests other program
configuration options
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Fig. 4 MRMPlus‘ Visualization – Mini-validation of Repeatability. For each monitored transition, low, medium and high concentration assays are
profiled over five days with replicate experiments on each day. Figure shows MRMPlus-generated ‘repeatability’ performance for a sample peptide –
EDALNETR. It includes performance plots for the summed transition at the a low, medium and high concentration level. Y-axis coordinates are
median estimate of replicate measurements at the different concentration levels while the X-axis coordinates are the days when the experiments were
performed. Current implementation of MRMPlus [by default] generates repeatability performance plot for peptides summed transition
Fig. 3 MRMPlus‘ Visualization – Response Curve. For each monitored transition of a particular peptide, experimental values are derived at serial
dilution levels (calibration points). Experiments at respective dilution level are performed in replicates. Figure shows MRMPlus-generated response
curves for a sample peptide – EDALNETR. It includes performance plots for the peptide associated transitions (2.y4.1, 2.y5.1, and 2.y6.1) and
summed transition
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Conclusions
MRMPlus facilitates MRM assay development. By align-
ing its workflow with Skyline, a previously established
tool for building, analyzing, and refining targeted mass
spectrometry methods and the resulting data, MRMPlus
streamlines and simplifies assay performance estimation.
Future developments of MRMPlus are anticipated to be
integrated to the Skyline open-source tool for an even




Operating system: Platform independent
Programming Language: Java
License: The BSD 3-Clause License
Other requirements: Please see documentation here -
https://bitbucket.org/paiyetan/mrmplusgui/wiki/Home.
Any restrictions to use by non-academics: None
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Additional file 1: Table S1. Sample Skyline-derived response curve
experiment input to MRMPlus. (TXT 128 kb)
Additional file 2: Table S2. Sample user-defined response experiment
metadata file. (TXT 1 kb)
Additional file 3: Table S3. Sample user-defined dilution file. (TXT 130
bytes)
Additional file 4: Table S4. Sample Skyline-derived repeatability
experiment input to MRMPlus. (TXT 199 kb)
Additional file 5: Table S5. Sample MRMPlus computed assay
performance metrics for the response curve experiments. (TXT 28 kb)
Additional file 6: Table S6. Sample MRMPlus computed assay
performance metrics for assay repeatability experiments. (TXT 13 kb)
Additional file 7: Figure S1. MRMPlus visualizations. (PNG 176 kb)
Additional file 8: Figure S2. MRMPlus visualization showing a sample
global performance view across all assayed peptide transitions. The x-axis
represents individual peptide transitions (including summed transitions).
The y-axis represent the computed coefficient of variations (inter-assay,
intra-assay, and total) at a median level concentration. (PNG 67 kb)
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